^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    TG02

    i
    Associations

    News

    Trials
    Company:
    Circio Holding, IOVaxis
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    A non-randomised open-label exploratory 'window of opportunity' study of TG02 treatment in patients with locally advanced primary and recurrent RAS mutant colorectal cancer. (PubMed, Heliyon)
    Low numbers limit conclusive clinical outcome reporting. High PD-1 expression on post-treatment TILs encourages the addition of an immune checkpoint inhibitor to TG02 and potentially other studies of peptide vaccines in future studies.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • RAS (Rat Sarcoma Virus) • CSF2 (Colony stimulating factor 2)
    |
    KRAS mutation • RAS mutation • PD-1 overexpression • PD-1 expression
    |
    zotiraciclib (TG02) • TG02